Circulating tumor cell technology to advance cancer therapeutic development, treatment matching and resistance monitoring
SAN DIEGO and NEW YORK CITY – November 26, 2014 – Epic Sciences, a precision diagnostics company dedicated to improving the treatment of cancer, today announced that Murali Prahalad, Ph.D., president and CEO, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 9:30 a.m. ET at The New York Palace in New York City.
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic’s no cell left behind™ technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.